Objectives Stage IIIA non-small cell lung cancer (NSCLC) is heterogeneous in tumor burden, and its treatment is variable. Whole-body metabolic tumor volume (MTV WB ) has been shown to be an independent prognostic index for overall survival (OS). However, the potential of MTV WB to risk-stratify stage IIIA NSCLC has previously been unknown. If we can identify subgroups within the stage exhibiting significant OS differences using MTV WB , MTV WB may lead to adjustments in patients' risk profile evaluations and may, therefore, influence clinical decision making regarding treatment. We estimated the risk-stratifying capacity of MTV WB Nucl Med Mol Imaging (2017) 44:1275-1284 DOI 10.1007 IIIA patients with high MTV WB (above 29.2 mL) (p < 0.01 
IIIA patients with high MTV WB (above 29.2 mL) (p < 0.01). There was no OS difference between the low MTV WB stage IIIA and the cohort of stage IIB patients (p = 0.485), or between the high MTV WB stage IIIA patients and the cohort of stage IIIB patients (p = 0.459). Similar risk-stratification capacity of MTV WB was observed in a large range of cutoff values from 15 to 55 mL in stage IIIA patients. Conclusions Using MTV WB cutoff points ranging from 15 to 55 mL with an optimal value of 29.2 mL, stage IIIA NSCLC may be effectively stratified into subgroups with no significant survival difference from stages IIB or IIIB NSCLC. This may result in more accurate survival estimation and more appropriate risk adapted treatment selection in stage IIIA NSCLC. 
Background
Current standard-of-care treatment and prognostic assessment of NSCLC depends primarily on the TNM staging system, an internationally accepted staging system developed and maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) [1] [2] [3] [4] [5] [6] [7] .
In the forthcoming 8th edition of the TNM staging system [8] , stage IIIA remains highly heterogeneous due to variations in tumor burden of the primary tumor and nodal metastases, as it is composed of T1a-T2bN2M0, T3-4N1M0, and T4N0M0 disease. The T lesion size ranges from ≤1 cm (T1a) to >7 cm (T4), and the N lesions range from microscopic metastasis to bulky massive lymphadenopathy. The management of stage IIIA NSCLC varies considerably: chemotherapy (neoadjuvant, combined with radiation, or adjuvant), radiation therapy (in combination or post-operative), and surgery (pneumonectomy or lobectomy in various combinations with chemotherapy and radiation) have all been evaluated in multiple studies [9] [10] [11] [12] [13] [14] [15] [16] . Treatment options for stages IIB and IIIB NSLCL are somewhat better defined. In stage IIB disease, surgical resection is considered to be the standard of care, and chemotherapy and/or radiation may be added to the treatment plan [17] . On the other hand, for stage IIIB NSLCL patients, surgery is rarely considered, and chemoradiation remains the mainstay of treatment [18] . Based on the International Association for the Study of Lung Cancer (IASLC) staging project results, 18% of NSCLC patients are diagnosed with TNM stage IIIA disease [8] . Further risk-stratification of these patients could create new treatment opportunities e.g., surgical lobectomy for low-risk patients, or more appropriate treatments for high-risk patients.
In NSCLC, MTV WB , which is the sum of tumor volumes of all metabolically active tumoral lesions in the whole body ( Fig. 1 ) measured on baseline FDG PET/CT, has been shown to be a prognostic index independent of TNM stage, tumor SUV, and other clinical prognostic indicators including age, gender, performance status, treatment type, and tumor histology [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Compared to TNM staging, MTV WB has greater discriminatory power in prognosis, as measured by Cstatistics [22, 27, 28] 
Materials and methods

Patients
We performed an institutional review board-approved retrospective review of 330 patients with new clinical stage IIB, IIIA, and IIIB NSCLC diagnosis at a single institution between 2004 and 2014. This study is in compliance with the Health Insurance Portability and Accountability Act. The study population includes the 330 consecutive NSCLC patients diagnosed with NSCLC in our hospital system from 2004 to 2014 who had a baseline PET/CT scan. The patient's demographic information including age and gender, tumor histology type, and treatment history were compiled by our institution's Cancer Registry and verified by the authors. Clinical TNM staging was assigned using the 8th edition system for clinical staging [8, 30, 31] , and was based on whole-body PET/CT scans and contrast infused CT of the chest or chest and abdomen by the authors. Confirmatory mediastinal nodal biopsy results were also used for clinical staging in 62 of 137 stage IIIA patients who had invasive mediastinal staging via brochoscopy/mediastinoscopy, thoracoscopy, or endobronchial ultrasound bronchoscopy.
Survival status and dates of death were determined through clinical follow-up via the electronic medical records and the Social Security Death Index by our Cancer Registry.
The following inclusion criteria were used for this study: (1) Presence of a baseline (pre-treatment) wholebody PET/CT, (2) no known brain metastasis (the standard PET/CT scan does not include the entire brain in the field of view), (3) no history of concurrent (within 2 months of PET/CT scan) or previous (< 5 years from PET/CT scan) diagnosis with another primary cancer, (4) stage IIB, IIIA, or IIIB NSCLC. A total of 2180 patients were excluded from 2510 patients diagnosed or treated in our institution from 2004 to 2014 (Fig. 2) . Overall survival (OS) was used as the primary endpoint of our analysis. Survival time was calculated starting from the baseline PET/CT, and survival endpoint was date of death from any cause. Patients who were alive at last contact or lost to follow-up were censored on the date of last known contact.
FDG PET/CT data acquisition and analysis
PET/CT techniques
The protocol for PET/CT imaging and the MTV WB calculation have been described previously by our group [22, 27] . In brief, in our institution, from January 1, 2004 to March 15, 2012, 18F-FDG PET/CT images were acquired using a highresolution bismuth-germanate detector PET scanner as well as a dual-slice CT system (Reveal HD, CTI, Knoxville, TN, USA). After March 15, 2012, a Siemens mCT scanner (Siemens Healthcare, Knoxville, TN, USA) was used in our institution. In 207 study patients (62 with stage IIB, 78 with stage IIIA, and 67 with stage IIIB), PET/CT scans were obtained with the former scanner, and in 47 patients (four with stage IIB, 24 with stage IIIA, and 19 with stage IIIB), the PET/ CT scans were acquired with latter scanner. In our institution, the PET/CT scans were performed in accordance with National Cancer Institute guidelines. Patients were instructed to fast for at least 4 h, and plasma glucose levels were less than 200 mg/dL. A dose of 370-555 MBq of 18F-FDG was given IV. 
Measurements from PET/CT scans
Two board-certified radiologists with PET/CT imaging experience measured the MTV WB for each patient using the PET-edge tool of the MIMvista software (MIMvista Corp, Cleveland, OH, USA), which was based on gradient method for tumor
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Patients excluded due to NSCLC stages other than IIB, IIIA, or IIIB (n=636). segmentation (Fig. 1) [22] . Discrepancies between their assessments were resolved by consensus through discussion.
Survival analysis
To determine the optimal cutoff value for MTV WB , sequential log-rank tests were performed with various cutoffs through the range of stage IIIA MTV WB values for our patient sample. For each cutoff value, two subgroups were formed based on whether the patient had an MTV WB lower than the cutoff for stage IIIA [IIIA(−)] or greater than the cutoff [IIIA(+)]. These subgroups were then compared to the adjacent clinical stage cohorts (stages IIB and IIIB) in the survival analyses. The optimal cutoff value was considered to be the value which maximized the log-rank χ 2 result for stage IIIA(−) vs. stage IIIA(+) while minimizing the log-rank χ 2 result for both stage IIB vs. IIIA(−) and stage IIIA(+) vs. IIIB. This effectively allows us to find the MTV WB cutoff value for which the stage IIIA(−) patients and the stage IIIA(+) patients had the greatest and statistically significant difference in OS, while maintaining OS of the stage IIIA(−) patients not significantly different from that of the stage IIB patients, and OS of the stage IIIA(+) patients not significantly different from that of the stage IIIB patients [32] [33] [34] . We also determined the range of cutoff values which showed similar risk-stratification results, with statistically different survival curves when comparing stage IIIA(−) vs. IIIA(+), while maintaining no significant difference between survival curves for stage IIB vs. IIIA(−) and stage IIIA(+) vs. IIIB.
Schoenfeld residuals tests were performed to test deviation from the proportional hazards assumption for each covariate. Survival analysis was performed using univariate and multivariate Cox regression models. In the multivariate Cox regression model, sex, age (greater than vs. less than 70 years), and tumor histology (adenocarcinoma vs. others) were used as the covariates in addition to MTV WB . Kaplan-Meier survival curves with log-rank test were generated for illustrative purpose, and comparisons among groups used the log-rank test.
For each statistical test, a two tailed p-value of <0.05 was used to determine statistical significance. Statistical analysis was performed using STATA 13.0 software (StataCorp LP, College Station, TX, USA).
Results
The patient cohort and tumor characteristics are summarized in Table 1 . Follow-up was complete to death or until the end of data collection in 87.9% of patients. Specifically, 70.6% of the patients (233/330) died during the follow-up period. Median follow-up of the 97 surviving patients was 3.27 years (25th percentile: 1.86 years, 75th percentile: 5.86 years). Of the patients who were alive at last contact, 90.7% (88/97) had follow-up for more than one year. The last patient included was diagnosed in December, 2014.
Median MTV WB was 37.11 mL for stage IIB (n = 83), 39.45 mL for stage IIIA (n = 137), and 86.98 mL for stage IIIB (n = 110). Median survival time for stage IIB was 3.65 years (86.7% survival at 1 year, 57.1% at three years, and 41.6% at 5 years). Median survival time for stage IIIA was 1.88 years (74.0% survival at 1 year, 38.2% at 3 years, and 25.9% at 5 years). Median survival time for stage IIIB was 1.17 years (56.5% survival at 1 year, 20.3% at 3 years, and 13.9% at 5 years). Kaplan-Meier curves and log-rank tests showed a significant OS difference between stages IIIA and IIB (p = 0.005) and between stages IIIB and IIIA (p = 0.004) (Fig. 3) .
Using the sequential log-rank test method described in the previoussection,theoptimalcutoffvalueforMTV WB wasdetermined to be 29.2 mL, which divided the stage IIIA patients into two subgroups -44.5% of those with MTV WB ≤ 29.2 mL designated as stage IIIA(−), and 55.5% of those with MTV WB > 29.2 mL 
Discussion
Our results show that patients with stage IIIA NSCLC may be stratified into a cohort with a more comparable survival profile to either stage IIB or IIIB by using stratification based on MTV WB . The risk stratification ability of this method is robust as demonstrated by the consistent results over a wide range of MTV WB cutoff points from 15 to 55 mL, with the optimal cut-point value of 29.2 mL. This provides a quantitative measure that care providers may use to help determine whether a patient with stage IIIA NSCLC should undergo treatment more appropriate for stage IIIB patients versus options which are typically reserved for less advanced disease (stage IIB) with consideration of other clinical prognostic factors. This risk-stratification in stage IIIA NSCLC may have a complementary role to the TNM staging system for better treatment decision making with the potential to produce better overall patient survival for a significant portion of NSCLC patients. Quite interestingly, the optimal value obtained in this study is very close to the one recently proposed by Bazan et al. in patients with inoperable stage III NSCLC treated with definitive chemoradiation [35] . Based on secondary analysis of 230 patients with MTVwb in database of the American College of Radiology Imaging Network (ACRIN) 6668/Radiation Therapy Oncology Group 0235, they found that patients with MTVwb >32 mL (median value) vs. ≤32 mL had significantly worse median OS (14.8 vs. 29.7 months) [35] .
In the current study, we staged the study patients according to the 8th edition of the TNM staging system to make this study clinically relevant [8] . Furthermore, using PET/ CT to determine MTV WB is an additional useful function to the current standard use of the modality in TNM staging as MTV WB is not used in NSCLC TNM staging.
This quantitative MTV WB value is not currently used in clinical practice for NSCLC staging even though PET/CT has long been used in tumor TNM staging and in visual evaluation of metabolic tumor volume by physicians. Currently all imaging modalities used for NSCLC care (PET/CT, CT, and MRI) provide intrinsically volumetric (3D) data; therefore, adding tumor volumetric measurement to clinical NSCLC staging requires only some additional image processing. In the current study we used FDG PET/CT scans for quantitative MTV WB measurement, because numerous other studies have shown that PET/CT is more accurate than CT or MRI for lesion characterization in various cancers, including NSCLC [36] [37] [38] [39] [40] [41] [42] , which is important because it is often difficult to tell tumor from infection, inflammatory change or posttherapeutic change on CT and MR images. In addition, oncologic PET/CT scans are routinely performed from "eyes to thighs" [43] , thus facilitating MTV WB measurements for improving staging. Moreover, a study in head and neck cancer that compared tumor volume measured on CT, MRI, and 18F-FDG PET scans found that the PETderived MTV was the closest to the reference tumor volume from surgical specimens [44] , and in NSCLC, 18F-FDG PET/CT fusion images were found to more faithfully reflect pathological tumor size measurement than 18F-FDG PET alone or CT alone [45] .
Measurement of MTV WB in NSCLC on PET/CT has low inter-observer variability in NSCLC (mean concordance correlation coefficient greater than 0.94) [22, 28, 46] , and measurement of MTV WB is now clinically practical. Recently we have demonstrated semi-automatic tumor segmentation and quantification can be used in primary tumor of NSCLC for this purpose and is less time consuming than manual tumor segmentation and quantification [45] . We also have demonstrated that MTV measurement of the primary tumor in NSCLC varies less than SUV measurement between 1 h and 2 h after FDG injection [47] .
The PET/CT scans of the study cohort were performed with different scanners and at different institutions. Two hundred and fifty-four of the 330 patients were scanned with two scanners in our institution (207 on the older scanner and 47 on the newer), and 76 of patients were There are some limitations of this study. First, this is a retrospective study and treatment received was determined by prevailing practice protocols and old editions of the TNM staging system from 2004 to 2014. Second, the study was performed at a single institution, and although the overall patient sample size was large, the individual stage cohorts had less robust sample sizes; however, the power of our statistical tests remained adequate. Third, while the gradient method used in the current study for the segmentation of the tumoral lesions has been reasonably tested [48, 49] , it is not the method used by the majority of centers. Future validation with different tumor segmentation software is necessary. However, this limitation may be minor as a similar MTVwb cutoff point was determined by Bazan et al. [35] , using opensource software application [50] . Future work with large cohorts of patients may be used to validate the findings. Comparison with data from other institutions as well as validation with a prospective study will be helpful to confirm and fine-tune the cutoff values for more accurate NSLCL staging.
Conclusion
Using MTV WB cutoff points ranging from 15 to 55 mL with an optimal cutoff value of 29.2 mL, stage IIIA NSCLC may be effectively stratified into subgroups with no statistically significant survival difference from stages IIB or IIIB NSCLC. This may result in more accurate survival estimation and more appropriate risk adapted treatment selection; i.e. therapy options including surgery for low risk patients and bimodality therapy of chemoradiation for high risk patients.
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